Posters

      A Mechanistic Study Using 2D-Page Proteomic Approach To Investigate The Effect Of Cigarette Smoke-Induced COPD, Cessation And Switching To Modified Risk Tobacco Product In The Lungs of C57BL/6 Mice

      Dijon, S.; Schneider, T.; Elamin, A.; Veljkovic, E.; Phillips, B.; Titz, B.; Martin, F.; Ivanov, N.; Hoeng, J.; Peitsch, M.

      Conference date
      Oct 5, 2014
      Conference name
      HUPO 2014
      Link to more information
      Topic
      Summary

      In this study, the impact on the development of emphysema/COPD following inhalation of aerosol from two tobacco products, a reference cigarette (3R4F) and a prototypic modified risk tobacco product (pMRTP), was evaluated in C57BL/6 mice. The mice were exposed to an aerosol from 3R4F (750 µg/L TPM, 34.4 µg/L nicotine), pMRTP (nicotine concentration-matched) or filtered air (sham) for 4 hours per day, 5 days per week, up to 7 months. After 2 months of exposure to 3R4F, switching and cessation groups were exposed to pMRTP or filtered air, respectively. To analyze the progression of emphysema at molecular level, quantitative proteomics approach using 2d-page was performed on lung tissues at months 1, 3, 5 and 7. Six biological replicates were analyzed to assess repeatability and reproducibility across measurements. The gel images were aligned and analyzed using imaging software (samespots; totalab). The differentially expressed proteins/spots were excised, digested and analyzed using MALDI-TOF/TOF for protein identification by conducting the searches against the mouse Uniprot/Swissprot reference database. The protein profiles showed minimal changes associated with pMRTP exposure, and recovery near to sham-exposed levels following either switching or cessation. The generated proteomics datasets of the differentially expressed proteins will be presented (e.g. ctsd, fabp5; sftpa). Exposure of mice to mainstream CS-induced acute inflammatory changes in the lung and airways in a time-dependent manner across. The results complement the data from iTRAQ LC MS/MS approach on lung tissues, verification by reverse-phase microarray and the analysis of the other endpoints (transcriptomics) within the study. The generated output will further establish the foundation of PMI’s systems biology approach to assess the impact of pMRTP on biological systems. 

      Related Publications

      Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System 2.2

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

      Aerosol Chemistry

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.